Pharmaceuticals DC $500K+ Reviewed

Barda Drive Ez-Baa (Ezbaa - 22-100-Sol-00003)

HHS

WASHINGTON, DC

vaccines on demand host-directed therapeutics medical countermeasures lung therapeutics host diagnostics $500K+

Posted Apr 24, 2024

Due Oct 18, 2027

Description

The BARDA DRIVe EZ-BAA (EZ-BAA-22-100-SOL-00003), issued by HHS, solicits research and development proposals across multiple Areas of Interest (AOIs) focused on medical countermeasures, including ReDIRECT, Lab at Home, Digital MCMs, Host-Directed Therapeutics, Healing Lungs, DRIVe Forward, Vaccines on Demand, ReBooT, Host-Based Diagnostics, and REPAIR. These AOIs target innovative solutions for diagnostics, therapeutics, vaccines, and related technologies to address public health threats. Eligible bidders include biotech firms, pharmaceutical companies, academic researchers, and medical device developers with relevant expertise in advanced R&D.

This bid is 98% medical related

A strong match for healthcare vendors

Why we classified this as medical

BARDA (Biomedical Advanced Research and Development Authority) under HHS is soliciting R&D proposals via EZ-BAA for medical countermeasures including Digital MCMs, Host-Directed Therapeutics, Vaccines on Demand, and Healing Lungs. Areas of interest like ReDIRECT, Lab at Home, and REPAIR focus on advanced biomedical technologies, diagnostics, and therapeutics directly relevant to medical vendors in pharmaceuticals, devices, and diagnostics.

View Original Source

Save for Later

Send to Pipeline